The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial

作者：Xinxin Wang, Shuo Li, Yihong Sun, Kai Li, Xian Shen, Yingwei Xue, Pin Liang, Guoli Li, Luchuan Chen, Luchuan Chen, Qun Zhao, Guoxin Li, Weihua Fu, Liang Han, Hairong Xin, Jian Suo, Xuedong Fang, Zhichao Zheng, Zekuan Xu, Huanqiu Chen, Yanbing Zhou, Yulong He, Hua Huang, Linghua Zhu, Kun Yang, Jiafu Ji, Yingjiang Ye, Zhongtao Zhang, Fei Li, Xin Wang, Yantao Tian, Sungsoo Park, Lin Chen, Lin Chen · 发表于：BMC Cancer · 年份：2021 · DOI：10.1186/s12885-020-07764-7 · 被引用次数：38 · 研究领域：Gastric Cancer Management and Outcomes、Gastrointestinal Tumor Research and Treatment、Helicobacter pylori-related gastroenterology studies

BACKGROUND: Curing locally advanced gastric cancer through surgery alone is difficult. Adjuvant and neoadjuvant chemotherapy bring potential benefits to more patients with gastric cancer based on several clinical trials. According to phase II studies and guidelines, SOX regimen as neoadjuvant chemotherapy is efficient. However, the optimal duration of neoadjuvant chemotherapy has not been established. In this study, we will evaluate the efficacy and safety of different cycles of SOX as neoadjuvant chemotherapy for patients with locally advanced gastric cancer. METHODS: RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study which will enroll 524 patients in total. Eligible patients will be registered, pre-enrolled and receive three cycles of SOX, after which tumor response evaluations will be carried out. Those who show stable disease or progressive disease will be excluded. Patients showing complete response or partial response will be enrolled and assigned into either group A for another three cycles of SOX (six cycles in total) followed by D2 surgery; or group B for D2 surgery (three cycles in total). The primary endpoint is the rate of pathological complete response and the secondary endpoints are R0 resection rate, three-year disease-free survival, five-year overall survival, and safety. DISCUSSION: This study is the first phase III randomized trial to compare the cycles of neoadjuvant chemotherapy using SOX for resectable locally advance...